Vertex Pharmaceuticals Inc (VRTX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Tr...
Vertex Pharmaceuticals Inc's revenue increased 8.9% year over year, from $11.02B to $12.00B.
Net income increased 838.1% over the same period, from $-535.6M to $3.95B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 605% in total.
Operating cash flow grew 837.2% to $3.63B.
Vertex Pharmaceuticals Inc maintains a strong net profit margin of 32.9%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Equity |
|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $2.77B+4.8% | $1.05B | $2.38B | $1.12B | $1.37B | $22.24B | $15.63B |
| Q4 FY2024 | $2.91B+5.1% | $913.0M | $2.49B | $1.03B | $584.6M | $22.53B | $16.41B |
| Q1 FY2025 | $2.77B-4.9% | $646.3M | $2.41B | $630.1M | $818.9M | $22.88B | $16.50B |
| Q2 FY2025 | $2.96B+7.0% | $1.03B | $2.56B | $1.15B | $1.07B | $24.04B | $17.18B |
| Q3 FY2025 | $3.08B+3.8% | $1.08B | $2.66B | $1.19B | $1.24B | $24.86B | $17.32B |
| Q4 FY2025 | $3.19B+3.7% | $1.19B | $2.72B | $1.21B | $498.0M | $25.64B | $18.67B |
| Q1 FY2026 | $2.99B-6.4% | $1.03B | $2.59B | $1.14B | $1.43B | N/A | N/A |
| Q2 FY2026 | $3.33B+11.6% | $1.10B | $2.84B | $1.25B | $1.13B | N/A | N/A |
Balance Sheet Summary (FY2025)
Vertex Pharmaceuticals Inc (VRTX) Financial Statements & Revenue History
Vertex Pharmaceuticals Inc (VRTX) is a US-listed stock operating in the Healthcare sector, specifically the Biotechnology industry trading at $502.00 with a market capitalization of $127. This page provides 42 historical financial statements for Vertex Pharmaceuticals Inc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Vertex Pharmaceuticals Inc reported revenue of $12.0 billion, representing 8.9% year-over-year growth. The net profit margin of 32.9% reflects strong profitability..
VRTX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Vertex Pharmaceuticals Inc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether VRTX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track VRTX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Vertex Pharmaceuticals Inc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of VRTX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use VRTX Financial Data
Investors use Vertex Pharmaceuticals Inc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare VRTX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how VRTX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View VRTX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Vertex Pharmaceuticals Inc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.VRTX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.